NeuroPace (NPCE)
(Delayed Data from NSDQ)
$8.99 USD
+0.48 (5.64%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $8.99 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NPCE 8.99 +0.48(5.64%)
Will NPCE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NPCE
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why
Other News for NPCE
NeuroPace (NPCE) Welcomes CMS Decision on RNS System Assignment
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with ...
NeuroPace 'commends' CMS for maintaining FY25 epilepsy reimbursement structure
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 | NPCE Stock News
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call